JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Item
http://www.wikidata.org/entity/Q38044736
Targeting survivin in cancer: novel drug development approaches.Emerging drugs for polycythemia vera.Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.Targeting hedgehog signaling in myelofibrosis and other hematologic malignanciesRole of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth.
P2860

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Item
http://www.wikidata.org/entity/Q38044736
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
@en
type
label
JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
@en
prefLabel
JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
@en
P2093
P2860
P304
P31
P356
10.1517/13543784.2012.721352
P407
P433
P478
P50
P577
P698